SANOFI AND SELECTA TARGET ALLERGIES.The article informs that Sanofi SA will be using synthetic vaccine particle technology from Selecta Biosciences Inc. for developing antigen-specific immunotherapies against a food allergen.M.M.EBSCO_bspChemical & Engineering News...
▲Selecta总裁兼首席执行官Werner Cautreels博士(图片来源:Selecta Biosciences官网) “我们对在EULAR上发布的这一扩展患者数据集中观察到的持续改善的临床活动感到非常高兴,并且相信它进一步证明了SEL-212具有改变慢性严重痛风治疗范式的潜力。它与现有疗法相比能提供更好和更持久的血清尿酸控制,减少发作和给药频率,”Select...
Lori Ellis NextGen After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory Annalee Armstrong MORE ON THIS TOPIC Business Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies February 20, 2025 · 2 min read ...
Shares of Selecta Biosciences (SELB) fell 2.3% on May 13 to close at $2.93 after the biotechnology company reported a loss in the first quarter. Meanwhile, revenues topped analysts’ expectations. Net loss for Q1 2021 came in at $24.6 million or $0.22 per share, compared to a net loss ...
近日,生物技术公司 Selecta Biosciences(纳斯达克股票代码:SELB)和 Ginkgo Bioworks(纽约证券交易所代码:DNA) 宣布将利用前者的 ImmTOR™ 免疫耐受平台和后者领先的细胞编程平台,合作开发具有改进转导、增强组织嗜性和降低免疫原性的下一代病毒衣壳。Ginkgo Bioworks 负责设计病毒衣壳,Selecta Biosciences 将在此后进行所有...
RUSNANO INVESTS IN BIND, SELECTA.The article reports on the 50-million-U.S. dollar investment of Russian Corp. of Nanotechnologies in nanomedicine-based firms Bind Biosciences and Selecta Biosciences in 2011.A.M.T.Chemical & Engineering News...